3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at 12pm ET, “Putting Science First in Rare Disease Studies”.
Listen to our experts and hear firsthand how Veristat’s track record as a leading rare disease CRO has powered success for our sponsors. We’ve directly supported over 350 rare disease clinical trials and nearly 40 marketing applications in the last five years alone.
The presentation is filled with actionable insights, with ample time allowed for your questions to be answered. Don't miss this opportunity to connect with our Experts and learn how Veristat is making a difference in the lives of patients with rare and ultra-rare diseases.
Find us at Booth 619 where we invite you to stop by and discover more about what makes Veristat a distinguished name in the clinical research industry. Our team will share insights and answer questions you might have about our Science-First approach that delivers several benefits to sponsors including the right design, reliable trial execution, and successful study completion to support rapid approval.
You can arrange a meeting by completing the form on the right side of this page. Discover how we can assist you in progressing your upcoming clinical trial or regulatory submission towards a successful outcome or explore our wide range of capabilities.
Website: WODC Congress USA 2024
Meet with us at WODC USA 2024 by filling out the form below.
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
3 min read
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...